Predictive and prognostic factors in RCC

**Location:** Room 7, Capital suite (level 3)

**Chairs:**
A. Mattei, Luzern (CH)
M. Oya, Tokyo (JP)
B. Peyronnet, Rennes (FR)

**Aims and objectives of this session**
To discuss various predictive and prognostic factors in RCC.

**Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.**

---

**640**

**Predictive factor of lymph node metastases in patients with non-metastatic renal cell carcinoma; multi-center study**

**By:** Kim K.S.¹, Kim H.W.², Kim J.C.³, Kwak C.⁴, Kim Y.-J.⁵, Kang S.H.⁶, Byun S-S.⁷, Kim S.H.¹, Hong S.-H.⁸

**Institutes:** Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Dept. of Urology, Incheon, South Korea, ²St. Paul’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Dept. of Urology, Seoul, South Korea, ³Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea., Dept. of Urology, Bucheon, South Korea, ⁴Seoul National University College of Medicine, Seoul, Korea, Dept. of Urology, Seoul, South Korea, ⁵Chungbuk National University College of Medicine, Cheongju, Korea, Dept. of Urology, Cheongju, South Korea, ⁶Korea University School of Medicine, Seoul, Korea, Dept. of Urology, Seoul, South Korea, ⁷Seoul National University Bundang Hospital, Seongnam, Korea, Dept. of Urology, Seongnam, South Korea, ⁸College of Medicine, The Catholic University of Korea, Seoul, Korea, Dept. of Urology, Seoul, South Korea

---

**641**

**Long-term assessment of mortality patterns after surgical treatment for non-metastatic kidney cancer: A competing risk analysis**

**By:** Larcher A.¹, Muttin F.¹, Nini A.¹, Trevisani F.¹, Ripa F.¹, Cianflone F.¹, Carenzi C.¹, Dell’Oglio P.¹, Rigatti P.², Dehó F.¹, Montorsi F.¹, Capitanio U.², Bertini R.¹

**Institutes:** IRCCS Ospedale San Raffaele, Urological Research Institute, Division of Oncology, Unit of Urology, Milan, Italy, ²Scientific Institute Istituto Auxologico Italiano, Department of Urology, Advanced Urotechnology Center, Milan, Italy

---

**642**

**External validation of the Mayo Clinic Stage, Size, Grade, and Necrosis score in patients with renal cell carcinoma and venous tumor thrombus**

**By:** Lorentz C.¹, Tai C.², Capitanio U.³, Carballido J.⁴, Ciancio G.⁵, Daneshmand S.⁶, Evans C.⁷, Gontero P.⁸, Hafekamp A.⁹, Höhenfellner M.¹⁰, Huang W.¹¹, Espinós E.¹², Martinez-Salamanca J.⁴, McKiernan J.¹³, Montorsi F.³, Pahernik S.¹⁰, Palou J.¹⁴, Pruthi R.¹⁵, Russo P.¹⁶, Scherr D.¹⁷, Spahn M.¹⁸, Terrone C.¹⁹, Tilki D.²⁰, Donoso C.²⁰, Vergho D.²¹, Wallen E.²², Zigeuner R.²¹, Libertino J.²², Master V.¹

**Institutes:** Emory University School of Medicine, Dept. of Urology, Atlanta, United States of America, ²University of California, Dept. of Epidemiology and Biostatistics, San Francisco, United States of America, ³University Vita-Salute, Dept. of Urology, Milan, Italy, ⁴Universidad Autónoma De Madrid, Dept. of Urology, Madrid, Spain, ⁵University of Miami, Dept. of Urology, Miami, United States of America, ⁶University of Southern California, Dept. of Urology, Los Angeles, United States of America, ⁷University of California-Davis, Dept. of Urology, Sacramento, United States of America, ⁸University of Turin, Dept. of Urology, Turin, Italy, ⁹University of Frankfurt, Dept. of Urology, Frankfurt, Germany, ¹⁰University of Heidelberg, Dept. of Urology, Heidelberg, Germany, ¹¹New York University School of Medicine, Dept. of Urology, New York, United States of America, ¹²University of Utah, Dept. of Urology, Salt Lake City, United States of America, ¹³University of Maryland, Dept. of Urology, Baltimore, United States of America, ¹⁴University of Southern California, Dept. of Urology, Los Angeles, United States of America, ¹⁵University of California-Davis, Dept. of Urology, Sacramento, United States of America, ¹⁶University of California, Davis, Dept. of Urology, Sacramento, United States of America, ¹⁷University of California, Davis, Dept. of Urology, Sacramento, United States of America, ¹⁸University of Turin, Dept. of Urology, Turin, Italy, ¹⁹University of Frankfurt, Dept. of Urology, Frankfurt, Germany, ²⁰University of Heidelberg, Dept. of Urology, Heidelberg, Germany, ²¹New York University School of Medicine, Dept. of Urology, New York, United States of America, ²²University of California, Davis, Dept. of Urology, Sacramento, United States of America.
643 The prevalence of renal cancer detected by abdominal ultrasonography in asymptomatic individuals: A systematic review and meta-analysis to inform the case for a screening study

By: Rossi S.1, Hsu R.3, Blick C.2, Goh V.3, Hanbury D.4, Nathan P.3, Nicol D.6, Fleming S.7, Sweeting M.8, Watson C.9, Wilson E.10, Stewart G.1

Institutes: 1Addenbrooke’s Hospital, Dept. of Urology, Cambridge, United Kingdom, 2Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom, 3Guy’s & St Thomas’ Hospitals NHS Trust, Dept. of Radiology, London, United Kingdom, 4Lister Hospital, Dept. of Urology, Stevenage, United Kingdom, 5Mount Vernon Cancer Centre, Dept. of Oncology, Northwood, United Kingdom, 6Royal Marsden Hospital, Dept. of Urology, London, United Kingdom, 7Ninewells Hospital, Centre for Forensic and Legal Medicine, Dundee, United Kingdom, 8University of Cambridge, Dept. of Public Health and Primary Care, Cambridge, United Kingdom, 9National Cancer Research Institute, Renal and Bladder Cancer Clinical Studies Group, London, United Kingdom, 10University of Cambridge, Cambridge Centre for Health Services Research, Cambridge, United Kingdom

644 Predictive and prognostic effect of inflammatory lymphadenopathies in renal cell carcinoma

By: Pecoraro A.1, Larcher A.1, Nini A.1, Muttin F.1, Stabile A.1, Di Trapani E.2, Carrozzi C.3, Trevisani F.3, De Cobelli F.2, Gaboardi F.1, Guazzoni G.3, Briganti A.1, Montorsi F.1, Bertini R.1, Capitanio U.1

Institutes: 1IRCCS Ospedale San Raffaele, Urological Research Institute, Dept. of Oncology and Urology, Milan, Italy, 2IRCCS Ospedale San Raffaele, Dept. of Radiology, Milan, Italy, 3Humanitas Clinical and Research Centre, Dept. of Urology, Milan, Italy

645 Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: Results of an international multi-institutional study on 2189 patients


Institutes: 1University Hospital Mainz, Dept. of Urology, Mainz, Germany, 2University Hospital Barcelona, Dept. of Urology, Barcelona, Spain, 3Medical University of Vienna, Dept. of Urology, Vienna, Austria, 4Instituto Nacional De Cancerologia, Dept. of Urology, Mexico, Mexico, 5Carl-Thiem-Klinikum Cottbus, Dept. of Urology, Cottbus, Germany, 6Vita-Salute San Raffaele University, Dept. of Urology, Milan, Italy, 7University of Muenster Medical Center, Dept. of Urology, Muenster, Germany, 8Hospital Bad Saarow, Dept. of Urology, Bad Saarow, Germany, 9Julius-Maximilians-University Medical Centre of Würzburg, Dept. of Urology, Würzburg, Germany, 10University Hospital Mannheim, Dept. of Urology, Mannheim, Germany, 11University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, 12University Hospital Carl Gustav Carus, Dept. of Urology, Dresden, Germany, 13Fundeni Clinical Institute, Centre of Urological Surgery, Dialysis and Renal Transplantation, Bucharest, Romania, 14Charles University In Prague, Dept. of Urology, Pilsen, Czech Republic, 15Medical University Graz, Dept. of Urology, Graz, Austria, 16Klinikum St. Elisabeth Straubing, Dept. of Urology, Straubing, Germany, 17Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany

646 Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease

Non-metastatic renal cell carcinoma follow-up, recurrences and outcomes – a RECUR database analysis

By: Dabestani S.1, Beisland C.2, Gudmundsson E.3, Stewart G.4, Lam T.5, Gietzmann W.6, Zakikhani P.6, Marconi L.7, Williams S.8, Powell T.9, Van Werkhoven E.10, Meijer R.P.11, Ljungberg B.11, Bex A.10

Institutes: 1Lund University, Dept. of Clinical Sciences, Malmö, Sweden, 2Haukeland University Hospital, Dept. of Urology, Bergen, Norway, 3Landspitali University Hospital, Dept. of Urology, Reykjavik, Iceland, 4University of Cambridge, Academic Urology Group, Cambridge, United Kingdom, 5University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, 6Aberdeen Royal Infirmary, Dept. of Urology, Aberdeen, United Kingdom, 7Coimbra University Hospital, Dept. of Urology, Coimbra, Portugal, 8Queen Mary University of London, Barts Cancer Institute, London, United Kingdom, 9The Netherlands Cancer Institute, Dept. of Bioinformatics and Statistics, Amsterdam, The Netherlands, 10The Netherlands Cancer Institute, Division of Surgical Oncology, Department of Urology, Amsterdam, The Netherlands, 11Umeå University, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden, 12University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands, 13University of Edinburgh, Dept. of Urology, Edinburgh, United Kingdom

Contemporary incidence and epidemiologic trends of brain metastases at renal cell carcinoma diagnosis

By: Gild P.1, Von Landenberg N.1, Sun M.1, Develasco G.2, Brasiantos P.3, Menon M.4, Fisch M.5, Chun F.5, Nguyen P.6, Trinh Q-D.7, Choueiri T.2

Institutes: 1Brigham and Women’s Hospital, Center For Surgery and Public Health and Division of Urologic Surgery, Boston, United States of America, 2Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, 3Dana-Farber Cancer Institute, Dept. of Cancer Biology, Boston, United States of America, 4Henry Ford Hospital, VUH Center For Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, 5University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 6Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Dept. of Medical Oncology, Boston, United States of America

Utilization and outcomes of T2 partial nephrectomy: A US population based analysis of the national cancer database

By: Hamilton Z., Fero K., Bloch A., Field C., Han D., Derweesh I.

Institutes: Moores Cancer Center, Dept. of Urology, La Jolla, United States of America

Contact with renal sinus is a significant risk factor for metastasis in pT1 clear cell renal cell
carcinoma
Institutes: 1Tokyo Medical And Dental Graduate School, Dept. of Urology, Tokyo, Japan, 2Saitama Cancer Center, Dept. of Urology, Saitama, Japan, 3Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan, 4Cancer Institute Hospital, Dept. of Urology, Tokyo, Japan, 5Tokyo Medical and Dental Graduate School, Dept. of Urology, Tokyo, Japan

Utility of chest x-ray in follow-up of pT1 renal cell carcinoma
Institutes: 1Cattinara Hospital; University of Trieste, Dept. of Urology, Trieste, Italy, 2Onze-Lieve-Vrouwziekenhuis, Dept. of Urology, Aalst, Belgium, 3University Hospital Careggi, Dept. of Urology, Florence, Italy

Organ confined renal cell carcinoma - are the current guidelines sufficient?
By: Frees S., Kamal M., Nestler S., Bidnur S., Neisius A., Jaeger W., Thomas C., Thüroff J., Roos F.
Institutes: 1University Medical Center, Dept. of Urology, Mainz, Germany, 2Hochtaunus Hospital Bad Homburg, Dept. of Urology, Bad Homburg, Germany, 3Vancouver Prostate Center, Dept. of Urology, Vancouver, Canada, 4University Medical Center, Dept. of Urology, Mannheim, Germany

Impact of hospital volume and surgeon volume on robot-assisted partial nephrectomy results: A multicenter study

Hospital activity and costs following partial nephrectomy: A comparison of surgical modalities using UK data
By: Camp C., O'Hara J., Hughes D., Adshead J.
Institutes: 1Hcd Economics, Dept. of Economics, Daresbury, United Kingdom, 2Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Dept. of Urology, Stevenage, United Kingdom